DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

BACKGROUND: Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib, a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS mutation status, and combination with docetaxel has demonstrated synergy in xenograft models. The aim of this study was to assess t...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Gupta, A, Love, S, Schuh, A, Shanyinde, M, Larkin, J, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Collins, L, Wise, A, Asher, R, Lisle, R, Middleton, MR
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Oxford University Press 2014

Παρόμοια τεκμήρια

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
ανά: Gupta, A, κ.ά.
Έκδοση: (2013)

Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
ανά: Gupta, A, κ.ά.
Έκδοση: (2020)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study
ανά: Robert, C, κ.ά.
Έκδοση: (2013)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
ανά: Robert, C, κ.ά.
Έκδοση: (2013)

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
ανά: Kirkwood, J, κ.ά.
Έκδοση: (2012)

Improved survival with MEK inhibition in BRAF-mutated melanoma.
ανά: Flaherty, K, κ.ά.
Έκδοση: (2012)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
ανά: K. Haslett, κ.ά.
Έκδοση: (2021-05-01)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
ανά: Edmund Poon, κ.ά.
Έκδοση: (2017-08-01)

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
ανά: Jessie Villanueva, κ.ά.
Έκδοση: (2013-09-01)

Immunological effects of BRAF+MEK inhibition
ανά: Paolo A. Ascierto, κ.ά.
Έκδοση: (2018-09-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
ανά: Eva Marie Erfurth, κ.ά.
Έκδοση: (2024-12-01)

Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib
ανά: Andrea Gazzin, κ.ά.
Έκδοση: (2024-06-01)

Identification of the Major Degradation Pathways of Selumetinib
ανά: Tahar Sif eddine Bouchema, κ.ά.
Έκδοση: (2022-11-01)

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
ανά: Pacey, S, κ.ά.
Έκδοση: (2016)

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
ανά: Anne L Estep, κ.ά.
Έκδοση: (2007-12-01)

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
ανά: Sara Bjursten, κ.ά.
Έκδοση: (2019-11-01)

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
ανά: Sarah J. Welsh, κ.ά.
Έκδοση: (2015-03-01)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
ανά: Blessie Elizabeth Nelson, κ.ά.
Έκδοση: (2023-05-01)

Effect of food on capsule and granule formulations of selumetinib
ανά: Sarit Cohen‐Rabbie, κ.ά.
Έκδοση: (2022-04-01)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
ανά: Hui-Ju Huang, κ.ά.
Έκδοση: (2021-06-01)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
ανά: Leijen, S, κ.ά.
Έκδοση: (2011)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
ανά: Leijen, S, κ.ά.
Έκδοση: (2011)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
ανά: Bengt Tholander, κ.ά.
Έκδοση: (2020-10-01)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
ανά: Ken Saijo, κ.ά.
Έκδοση: (2022-08-01)

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors
ανά: Anaïs Roeser, κ.ά.
Έκδοση: (2019-11-01)

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
ανά: Lovisa Falkman, κ.ά.
Έκδοση: (2024-04-01)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
ανά: Clare Judith Stones, κ.ά.
Έκδοση: (2013-05-01)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
ανά: Jan Leipe, κ.ά.
Έκδοση: (2019-06-01)

Case report: Metastatic BRAF V600E–mutated adult Wilms’ tumor with robust response to BRAF/MEK inhibitor therapy
ανά: Matthew R. Kroll, κ.ά.
Έκδοση: (2024-07-01)

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy
ανά: Shivshankari Rajkumar, κ.ά.
Έκδοση: (2022-04-01)

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation
ανά: J. Steininger, κ.ά.
Έκδοση: (2024-08-01)

REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
ανά: I. V. Samoylenko, κ.ά.
Έκδοση: (2017-11-01)

Exceptional response to rechallenge of BRAF/MEK inhibitors in patients with primary acquired resistance to targeted therapy
ανά: B. Ziółkowska, κ.ά.
Έκδοση: (2024-01-01)

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
ανά: Michael J. Vido, κ.ά.
Έκδοση: (2018-11-01)

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
ανά: Zeynep Eroglu, κ.ά.
Έκδοση: (2016-01-01)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
ανά: Raphael Reinhard, MD, κ.ά.
Έκδοση: (2018-03-01)

A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination
ανά: Manrose Singh, κ.ά.
Έκδοση: (2024-08-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
ανά: Sivakamavalli Jeyachandran
Έκδοση: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
ανά: Ariane Fizazi, κ.ά.
Έκδοση: (2024-11-01)

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study
ανά: Marit A. C. Vermunt, κ.ά.
Έκδοση: (2021-08-01)